Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
64actual
Sites
6
Countries
Canada, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2008-09-09 | actual | When the study began enrolling |
| Primary completion | 2009-07-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2008-09-11 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors
Intervention
- Drug: cediranib — also filed as RECENTIN
Primary outcome
what the primary-completion date above is the date OFTo assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin
measured PK assessments to be taken until Day 28. Days 7 and 14 PK parameters used to assess the primary variables.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed